Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.32 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.32 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.32 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.31 |
| ▸ | CNR1 | P21554 | 1/20 | 0.30 |
| ▸ | CNR2 | P34972 | 1/20 | 0.30 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.30 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9784280 | 0.77 | ACHE (0.40) | PTGS1PTGS2 | |
| SCHEMBL9650166 | 0.76 | TYMP (0.34) | RAPGEF4CNR2 | |
| SCHEMBL27618481 | 0.73 | GPR35 (0.34) | NISCHCNR1CNR2 | |
| SCHEMBL8463154 | 0.72 | AR (0.42) | — | |
| SCHEMBL6941941 | 0.71 | ACHE (0.40) | PTGS2NISCH | |
| SCHEMBL2012935 | 0.71 | RAPGEF4 (0.32) | RAPGEF4 | |
| SCHEMBL14480386 | 0.71 | — | — | |
| SCHEMBL28062187 | 0.68 | TAAR1 (0.32) | — | |
| SCHEMBL5822634 | 0.68 | MAP3K14 (0.37) | PTGS1PTGS2 | |
| SCHEMBL24499404 | 0.67 | DHODH (0.41) | RAPGEF4NISCH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 380 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240190880-A1 | SMALL MOLECULE DEGRADERS OF ESTROGEN RECEPTOR WITH CEREBLON LIGANDS | REGENTS OF THE UNIVERSITY OF MICHIGAN | 2024-06-13 | — | — | US | disclosed |
| US-20240190874-A1 | SMALL MOLECULE DEGRADERS OF ANDROGEN RECEPTOR | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2024-06-13 | — | — | US | disclosed |
| CN-114127073-B | Imidazopyrimidines as EED inhibitors and use thereof | 密歇根大学董事会 | 2024-05-31 | — | — | CN | disclosed |
| US-20240166647-A1 | Cereblon Ligands | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2024-05-23 | — | — | US | disclosed |
| US-20240150360-A1 | Small Molecule Degraders of CBP/p300 Proteins | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2024-05-09 | — | — | US | disclosed |
| WO-2024081410-A1 | PRODRUGS, FORMULATIONS AND METHODS THEREOF | OCULAR THERAPEUTIX, INC. (US) | 2024-04-18 | — | — | WO | disclosed |
| EP-4351552-A1 | COMBINATION THERAPIES WITH SETD2 INHIBITORS | Epizyme, Inc. (US) | 2024-04-17 | — | — | EP | disclosed |
| US-20240109892-A1 | POLY(ADP-RIBOSE) GLYCOHYDROLASE (PARG) INHIBITORS AGAINST COVID MACRODOMAIN AND METHODS OF USING THE SAME | NATIONAL INSTITUTES OF HEALTH | 2024-04-04 | — | — | US | disclosed |
| US-11944614-B2 | Imidazo[4,5-c]pyridine compounds as LSD-1 inhibitors | REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2024-04-02 | — | — | US | disclosed |
| WO-2024057277-A1 | DIAGNOSTIC PET IMAGING OF CARDIAC AMYLOIDOSIS | Beijing Lado Technology Co., Ltd. (CN) | 2024-03-21 | — | — | WO | disclosed |
| US-20110112052-A1 | SPIRO-OXINDOLE MDM2 ANTAGONISTS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2011-05-12 | — | — | US | disclosed |
| WO-2011050068-A2 | BIVALENT DIAZO BICYCLIC SMAC MIMETICS AND THE USES THEREOF | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2011-04-28 | — | — | WO | disclosed |
| US-20110046189-A1 | HETEROARYL-SUBSTITUTED BICYCLIC SMAC MIMETICS AND THE USES THEREOF | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2011-02-24 | — | — | US | disclosed |
| EP-2265604-A2 | HETEROARYL-SUBSTITUTED BICYCLIC SMAC MIMETICS AND THE USES THEREOF | The Regents of the University of Michigan (US) | 2010-12-29 | — | — | EP | disclosed |
| WO-2010041144-A2 | BETA-HYDROXY-GAMMA-AMINOPHOSPHONATES AND METHODS FOR THE PREPARATION AND USE THEREOF | NUCITEC S.A. DE C.V. (MX) | 2010-04-15 | — | — | WO | disclosed |
| US-20100087400-A1 | Beta-Hydroxy-Gamma-Aminophosphonates and Methods for the Preparation and Use Thereof | NUCITEC S.A. DE C.V. (MX) | 2010-04-08 | — | — | US | disclosed |
| EP-2167458-A1 | CHIRAL DIACHYLHYDRAZINE LIGANDS FOR MODULATING THE EXPRESSION OF EXOGENOUS GENES VIA AN ECDYSONE RECEPTOR COMPLEX | Intrexon Corporation (US) | 2010-03-31 | — | — | EP | disclosed |
| WO-2009126947-A2 | HETEROARYL-SUBSTITUTED BICYCLIC SMAC MIMETICS AND THE USES THEREOF | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2009-10-15 | — | — | WO | disclosed |
| US-20090163592-A1 | Chiral diacylhydrazine ligands for modulating the expression of exogenous genes via an ecdysone receptor complex | INTREXON CORPORATION (US) | 2009-06-25 | — | — | US | disclosed |
| WO-2008153801-A1 | CHIRAL DIACHYLHYDRAZINE LIGANDS FOR MODULATING THE EXPRESSION OF EXOGENOUS GENES VIA AN ECDYSONE RECEPTOR COMPLEX | INTREXON CORPORATION (US) | 2008-12-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240109892-A1 | POLY(ADP-RIBOSE) GLYCOHYDROLASE (PARG) INHIBITORS AGAINST COVID MACRODOMAIN AND METHODS OF USING THE SAME | MACROD2, MACROD1, PARG | RAPGEF4 2199/4885PTGS1 1385/4885PTGS2 1670/4885 |
| US-20090163592-A1 | Chiral diacylhydrazine ligands for modulating the expression of exogenous genes via an ecdysone receptor complex | NR2E3, CRYZ, TCF12 | RAPGEF4 4329/4885PTGS1 4396/4885PTGS2 3798/4885 |
| US-20110112052-A1 | SPIRO-OXINDOLE MDM2 ANTAGONISTS | TP53, MDM2, TP53BP1 | RAPGEF4 917/4885PTGS1 2391/4885PTGS2 2511/4885 |
| US-20240150360-A1 | Small Molecule Degraders of CBP/p300 Proteins | EP300, CREBBP, NCOR1 | RAPGEF4 2136/4885PTGS1 4268/4885PTGS2 4639/4885 |
| US-20240190874-A1 | SMALL MOLECULE DEGRADERS OF ANDROGEN RECEPTOR | AR, CYP19A1, ESRRA | RAPGEF4 4484/4885PTGS1 2002/4885PTGS2 3290/4885 |
| US-20240166647-A1 | Cereblon Ligands | CRBN, RB1, RBX1 | RAPGEF4 3767/4885PTGS1 3602/4885PTGS2 4551/4885 |
| US-11944614-B2 | Imidazo[4,5-c]pyridine compounds as LSD-1 inhibitors | KDM1A, KDM4A, KDM1B | RAPGEF4 686/4885PTGS1 1763/4885PTGS2 3577/4885 |
| US-20100087400-A1 | Beta-Hydroxy-Gamma-Aminophosphonates and Methods for the Preparation and Use Thereof | CPT1A, ACAT1, ABAT | RAPGEF4 3965/4885PTGS1 1420/4885PTGS2 2295/4885 |
| US-20110046189-A1 | HETEROARYL-SUBSTITUTED BICYCLIC SMAC MIMETICS AND THE USES THEREOF | BID, BAD, BIRC3 | RAPGEF4 2737/4885PTGS1 3364/4885PTGS2 3402/4885 |
| US-20240190880-A1 | SMALL MOLECULE DEGRADERS OF ESTROGEN RECEPTOR WITH CEREBLON LIGANDS | ESR1, CRBN, ESR2 | RAPGEF4 3725/4885PTGS1 2203/4885PTGS2 3425/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.